In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

A drug that targets two parts of the deadly Nipah virus protects against infection in hamsters. And once an animal is ...